万泰生物
(603392)
| 流通市值：809.30亿 | | | 总市值：809.30亿 |
| 流通股本：12.65亿 | | | 总股本：12.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,948,111,396.63 | 1,366,045,101.74 | 752,512,644.03 | 5,510,782,512.9 |
| 营业收入 | 1,948,111,396.63 | 1,366,045,101.74 | 752,512,644.03 | 5,510,782,512.9 |
| 二、营业总成本 | 1,928,979,981.89 | 1,289,398,978.35 | 672,195,652.14 | 3,878,716,787.18 |
| 营业成本 | 548,825,057.73 | 366,518,953.28 | 202,777,049.57 | 792,124,569.57 |
| 税金及附加 | 14,267,199.93 | 11,518,532.49 | 2,947,548.03 | 33,910,374.96 |
| 销售费用 | 443,746,679.62 | 314,996,757.34 | 203,521,797.98 | 1,595,094,413.98 |
| 管理费用 | 237,739,182.71 | 153,840,741.76 | 74,995,369.83 | 352,633,938.38 |
| 研发费用 | 726,214,438.31 | 479,931,276.6 | 206,734,939.77 | 1,197,930,447.47 |
| 财务费用 | -41,812,576.41 | -37,407,283.12 | -18,781,053.04 | -92,976,957.18 |
| 其中:利息费用 | 4,368,762.54 | 3,209,150.09 | 1,727,119.83 | 6,860,370.34 |
| 其中:利息收入 | 50,024,611.21 | 39,797,638.07 | 20,670,381.15 | 87,977,395.3 |
| 加:公允价值变动收益 | 13,336,212.46 | 8,554,260.2 | 3,982,807.18 | 24,657,151.78 |
| 加:投资收益 | 93,453,414.67 | 65,965,630.78 | 41,533,742.38 | 98,897,934.56 |
| 资产处置收益 | 1,183,739.81 | 102,259.03 | - | 221,616.08 |
| 资产减值损失(新) | -10,588,103.27 | -17,054,582.93 | -9,156,256.2 | -459,732,643.89 |
| 信用减值损失(新) | -25,470,766.68 | -32,726,238.69 | -35,022,141.98 | 22,547,590.21 |
| 其他收益 | 173,426,761.91 | 171,090,090.83 | 46,265,757.75 | 82,793,537.1 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 264,472,673.64 | 272,577,542.61 | 127,920,901.02 | 1,401,450,911.56 |
| 加:营业外收入 | 275,756.32 | 137,218.58 | 62,174.61 | 2,293,084.65 |
| 减:营业外支出 | 18,596,119.33 | 14,566,377.47 | 2,343,326.46 | 10,352,168.44 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 246,152,310.63 | 258,148,383.72 | 125,639,749.17 | 1,393,391,827.77 |
| 减:所得税费用 | -24,333,825.64 | -5,448,226.86 | -4,143,907.52 | 146,887,437.82 |
| 六、净利润 | 270,486,136.27 | 263,596,610.58 | 129,783,656.69 | 1,246,504,389.95 |
| 持续经营净利润 | 270,486,136.27 | 263,596,610.58 | 129,783,656.69 | 1,246,504,389.95 |
| 归属于母公司股东的净利润 | 266,649,096.74 | 260,480,462.16 | 125,708,151.18 | 1,247,679,723.81 |
| 少数股东损益 | 3,837,039.53 | 3,116,148.42 | 4,075,505.51 | -1,175,333.86 |
| (一)基本每股收益 | 0.21 | 0.21 | 0.1 | 0.99 |
| (二)稀释每股收益 | 0.21 | 0.21 | 0.1 | 0.99 |
| 九、综合收益总额 | 270,486,136.27 | 263,596,610.58 | 129,783,656.69 | 1,246,504,389.95 |
| 归属于母公司股东的综合收益总额 | 266,649,096.74 | 260,480,462.16 | 125,708,151.18 | 1,247,679,723.81 |
| 归属于少数股东的综合收益总额 | 3,837,039.53 | 3,116,148.42 | 4,075,505.51 | -1,175,333.86 |
| 公告日期 | 2024-10-25 | 2024-08-23 | 2024-04-26 | 2024-03-29 |
| 审计意见(境内) | | | | 标准无保留意见 |